T-DXd Outranks Treatment of Physicians’ Choice in QOL for HR+/HER2-Low/Ultralow MBC ...

Nivolumab (Opdivo), when given alone or in combination with ipilimumab (Yervoy), led to significant benefit in 10-year ...

The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

The duo of TAR-200 and cetrelimab was safe and efficacious in the neoadjuvant setting for certain patients with ...

Experts provide advice to patients and caregivers on managing oral and skin toxicities.

Adding relatlimab to nivolumab and chemotherapy improved efficacy but did not increase safety concerns in advanced-stage lung cancer.

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...